Could a brain lipid injection ease Parkinson's motor swings?
NCT ID NCT07585565
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests an injectable drug called GM1 in 276 people with Parkinson's disease who experience motor fluctuations (times when medication wears off). Participants are randomly assigned to receive GM1 or a placebo for about 12 weeks, while continuing their usual Parkinson's medications. The goal is to see if GM1 can increase the time they feel good movement control without troublesome involuntary movements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GM1 (monosialotetrahexosylganglioside sodium injection)
What this could lead to
If successful, this could provide a new option to help Parkinson's patients spend more time with good movement control and fewer side effects.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply broadly. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••